Drug intelligence / Profile preview

MZS Sleeping Aid

Development stage: Unknown
Lead developer: Aytu BioPharma
Modality: Small Molecules
Administration: Oral

Overview

MZS Sleeping Aid is a dietary supplement developed by Innovus Pharmaceuticals (through its subsidiary Novalere) designed to support sleep and manage sleep disorders. It is formulated as a tincture containing a combination of melatonin and hemp-derived cannabidiol (CBD) oil. Melatonin acts as an agonist at melatonin receptors (MT1 and MT2) to regulate the circadian rhythm and sleep-wake cycles, while CBD is included for its potential calming effects, likely interacting with the endocannabinoid system. The product is marketed as a nutraceutical rather than a prescription pharmaceutical and was launched in 2018.

Brand names: MZS Sleeping Aid

Targets

MTNR1A (MT1)MTNR1B (Melatonin Receptor 2)

Beyond the preview

Go deeper on MZS Sleeping Aid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MZS Sleeping Aid.

Explore the full profile